Teva faces backlash over acquisitions

(July 30, 2015) -- Consumer advocates concerned about the impact of consolidation in the generic drug industry on prices and supply have not been mollified by pharmaceutical giant Teva’s sudden decision to drop its bid for Mylan and, instead, to buy Allergan’s generic drug business....

Related Sections